Poniard Reports Positive Data From Phase II Prostate Cancer Trial
Poniard Pharmaceuticals, a biopharmaceutical company focused on oncology, has announced positive incremental data from its ongoing Phase II clinical trial of picoplatin in combination with docetaxel and prednisone as first-line therapy for metastatic hormone-refractory prostate cancer.
The expanded and updated results continued to show that picoplatin can be safely administered with full-dose docetaxel and prednisone, the standard treatment for hormone-refractory prostate cancer (HRPC), with no neurotoxicity observed. In addition, reductions of prostate specific antigen levels (PSA) of at least 50% were achieved in 78% of evaluable patients. Normalized PSA levels were achieved in 26% of patients.
In the ongoing Phase II trial, the efficacy and safety of intravenous picoplatin (120mg/m squared) administered every three weeks (21 days) in combination with full-dose docetaxel (75mg/m squared) with daily prednisone (5mg) as a first-line treatment are being evaluated in 30 patients with metastatic HRPC who have not received prior chemotherapy. PSA response is the primary endpoint; secondary endpoints include safety, response rate, time to progression and overall survival.
Robert Jager, chief medical officer of Poniard, said: “Additional data from this ongoing study may support the advancement of picoplatin into a Phase III clinical trial for HRPC. Our growing body of safety and efficacy data also supports the potential for additional uses of picoplatin as a combination therapy in the treatment of non-small cell lung and ovarian cancers where platinum and taxane combinations are currently used.”